Phio Pharmaceuticals is focused on developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYLTM) therapeutic platform. Immunotherapies harness our immune system to restore surveillance of tumors that evade detection – a potential curative medicine. INTASYLTM therapeutics can be used as a standalone treatment or in combination with other modalities.
Provided by Nasdaq.
Jun 3 - Jun 7, 20222022 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING
May 16 - May 19, 2022AMERICAN SOCIETY FOR GENE AND CELL THERAPY (ASGCT) 25TH ANNUAL MEETING
Apr 21 - Apr 22, 2022SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) TUMOR IMMUNE MICROENVIRONMENT: A HOLISTIC APPROACH WORKSHOP